Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995152 | 0.84 | PTPN2 (0.41) | MEN1CYP3A4ALOX15KMT2APTPN2 | |
| SCHEMBL995151 | 0.84 | PTPN2 (0.41) | MEN1CYP3A4ALOX15KMT2APTPN2 | |
| SCHEMBL8212898 | 0.82 | MEN1 (0.47) | MEN1CYP3A4ALOX15KMT2APTPN2 | |
| SCHEMBL11668697 | 0.82 | ALOX15 (0.47) | MEN1CYP3A4ALOX15KMT2APTPN2 | |
| SCHEMBL13280283 | 0.78 | MEN1 (0.44) | MEN1CYP3A4ALOX15KMT2APTPN2 | |
| SCHEMBL9793534 | 0.78 | MEN1 (0.44) | MEN1CYP3A4ALOX15KMT2APTPN2 | |
| SCHEMBL29473918 | 0.78 | MEN1 (0.44) | MEN1CYP3A4ALOX15KMT2APTPN2 | |
| SCHEMBL10632031 | 0.78 | MEN1 (0.44) | MEN1CYP3A4ALOX15KMT2APTPN2 | |
| SCHEMBL21627 | 0.78 | MEN1 (0.44) | MEN1CYP3A4ALOX15KMT2APTPN2 | |
| SCHEMBL5018789 | 0.76 | PTPN1 (0.42) | MEN1CYP3A4ALOX15KMT2APTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015397-A1 | Selective Aliphatic C-H Oxidation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-01-20 | — | — | US | disclosed |
| US-7829342-B2 | composition including a complex of a metal, a tetradentate ligand, at least one ancillary ligand, and a counterion is used for selective sp3 C H bond oxidation; includes a N-heterocyclic-N,N'-bis(pyridyl)-ethane-1,2-diamine group or a N,N'-bis(heterocyclic)-N,N'-bis(pyridyl)-ethane-1,2-diamine group | THE BOARD OF TRUSTEES OF THE UNIVERSIY OF ILLINOIS (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090221083-A1 | Selective Aliphatic C-H Oxidation | BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015397-A1 | Selective Aliphatic C-H Oxidation | AOC3, SOD3, AP3S1 | MEN1 4490/4885CYP3A4 1846/4885ALOX15 2139/4885 |
| US-20090221083-A1 | Selective Aliphatic C-H Oxidation | AOC3, SOD3, AP3S1 | MEN1 4490/4885CYP3A4 1846/4885ALOX15 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.